Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03874325
Title Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

estrogen-receptor positive breast cancer

Therapies

Durvalumab + Exemestane

Durvalumab + Letrozole

Anastrozole + Durvalumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.